Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor

Obinata, D; Takayama, K; Lawrence, MG; Funakoshi, D; Hara, M; Niranjan, B; Teng, L; Taylor, RA; Risbridger, GP; Takahashi, S; Inoue, S

Author(s): Obinata, D; Takayama, K; Lawrence, MG; Funakoshi, D; Hara, M; Niranjan, B; Teng, L; Taylor, RA; Risbridger, GP; Takahashi, S; Inoue, S;
Details: Publication Year 2024-05-02,Volume 24,Issue #1,Page 554
Journal Title: BMC Cancer
Publication Type: Research article
Abstract: BACKGROUND: Prostate cancer is dependent on androgen receptor (AR) signaling, and androgen deprivation therapy (ADT) has proven effective in targeting prostate cancer. However, castration-resistant prostate cancer (CRPC) eventually emerges. AR signaling inhibitors (ARSI) have been also used, but resistance to these agents develops due to genetic AR alterations and epigenetic dysregulation. METHODS: In this study, we investigated the role of OCT1, a member of the OCT family, in an AR-positive CRPC patient-derived xenograft established from a patient with resistance to ARSI and chemotherapy. We conducted a genome-wide analysis chromatin immunoprecipitation followed by sequencing and bioinformatic analyses using public database. RESULTS: Genome-wide analysis of OCT1 target genes in PDX 201.1 A revealed distinct OCT1 binding sites compared to treatment-naïve cells. Bioinformatic analyses revealed that OCT1-regulated genes were associated with cell migration and immune system regulation. In particular, C-terminal Binding Protein 2 (CTBP2), an OCT1/AR target gene, was correlated with poor prognosis and immunosuppressive effects in the tumor microenvironment. Metascape revealed that CTBP2 knockdown affects genes related to the immune response to bacteria. Furthermore, TISIDB analysis suggested the relationship between CTBP2 expression and immune cell infiltration in prostate cancer, suggesting that it may contribute to immune evasion in CRPC. CONCLUSIONS: Our findings shed light on the genome-wide network of OCT1 and AR in AR-positive CRPC and highlight the potential role of CTBP2 in immune response and tumor progression. Targeting CTBP2 may represent a promising therapeutic approach for aggressive AR-positive CRPC. Further validation will be required to explore novel therapeutic strategies for CRPC management.
Publisher: BioMed Central
Keywords: Male; Humans; *Prostatic Neoplasms, Castration-Resistant/genetics/pathology/metabolism; *Receptors, Androgen/metabolism/genetics; Mice; Animals; *Gene Expression Regulation, Neoplastic; *Octamer Transcription Factor-1/metabolism/genetics; *Alcohol Oxidoreductases/genetics/metabolism; Up-Regulation; Nerve Tissue Proteins/genetics/metabolism; Xenograft Model Antitumor Assays; Cell Line, Tumor; Drug Resistance, Neoplasm/genetics; Tumor Microenvironment; Signal Transduction; *Co-Repressor Proteins; Androgen receptor; Ctbp2; Oct1; Prostate cancer
Department(s): Laboratory Research
Publisher's Version: https://doi.org/10.1186/s12885-024-12298-3
Open Access at Publisher's Site: https://doi.org/10.1186/s12885-024-12298-3
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-07-17 03:02:39

Last Modified: 2024-07-17 03:11:20